Aligos Therapeutics, Inc. (ALGS)
ALGS Stock Price Chart
Explore Aligos Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ALGS price movements and trends.
ALGS Company Profile
Discover essential business fundamentals and corporate details for Aligos Therapeutics, Inc. (ALGS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Oct 2020
Employees
70.00
Website
https://www.aligos.comCEO
Lawrence Blatt
Description
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
ALGS Financial Timeline
Browse a chronological timeline of Aligos Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$1.41, while revenue estimate is $24.68m.
Earnings released on 7 May 2026
EPS came in at -$2.21 surpassing the estimated -$2.29 by +3.49%, while revenue for the quarter reached $2.83m , beating expectations by +1.03k%.
Earnings released on 5 Mar 2026
EPS came in at -$1.91 surpassing the estimated -$2.49 by +23.19%, while revenue for the quarter reached $169.00k , missing expectations by -61.59%.
Earnings released on 6 Nov 2025
EPS came in at -$3.04 falling short of the estimated -$2.09 by -45.45%, while revenue for the quarter reached $741.00k , beating expectations by +177.87%.
Earnings released on 6 Aug 2025
EPS came in at -$1.53 surpassing the estimated -$2.35 by +34.89%, while revenue for the quarter reached $965.00k , beating expectations by +122.69%.
Earnings released on 6 May 2025
EPS came in at -$2.11 surpassing the estimated -$2.80 by +24.64%, while revenue for the quarter reached $311.00k , missing expectations by -37.80%.
Earnings released on 10 Mar 2025
EPS came in at -$3.41 falling short of the estimated -$2.63 by -29.66%, while revenue for the quarter reached $629.00k , beating expectations by +25.80%.
Earnings released on 6 Nov 2024
EPS came in at -$3.07 falling short of the estimated -$2.15 by -42.79%, while revenue for the quarter reached $1.27m , beating expectations by +192.85%.
Stock split effective on 19 Aug 2024
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 6 Aug 2024
EPS came in at $0.75 surpassing the estimated -$4.00 by +118.75%, while revenue for the quarter reached $1.06m .
Earnings released on 7 May 2024
EPS came in at -$5.50 falling short of the estimated -$4.75 by -15.79%, while revenue for the quarter reached $986.00k .
Earnings released on 12 Mar 2024
EPS came in at -$5.50 surpassing the estimated -$6.75 by +18.52%, while revenue for the quarter reached $2.68m , beating expectations by +67.56%.
Earnings released on 2 Nov 2023
EPS came in at -$10.25 surpassing the estimated -$12.00 by +14.58%, while revenue for the quarter reached $3.24m , beating expectations by +102.44%.
Earnings released on 3 Aug 2023
EPS came in at -$10.75 surpassing the estimated -$12.50 by +14.00%, while revenue for the quarter reached $6.89m .
Earnings released on 4 May 2023
EPS came in at -$13.25 falling short of the estimated -$12.25 by -8.16%, while revenue for the quarter reached $2.72m , beating expectations by +91.76%.
Earnings released on 9 Mar 2023
EPS came in at -$12.75 falling short of the estimated -$12.25 by -4.08%, while revenue for the quarter reached $3.54m , beating expectations by +105.64%.
Earnings released on 2 Nov 2022
EPS came in at -$11.00 surpassing the estimated -$14.25 by +22.81%, while revenue for the quarter reached $4.11m , beating expectations by +447.47%.
Earnings released on 4 Aug 2022
EPS came in at -$11.75 surpassing the estimated -$16.25 by +27.69%, while revenue for the quarter reached $3.69m .
Earnings released on 4 May 2022
EPS came in at -$21.00 falling short of the estimated -$16.50 by -27.27%, while revenue for the quarter reached $2.57m , beating expectations by +17.74%.
Earnings released on 10 Mar 2022
EPS came in at -$22.25 falling short of the estimated -$20.75 by -7.23%, while revenue for the quarter reached $367.00k .
Earnings released on 4 Nov 2021
EPS came in at -$19.50 surpassing the estimated -$20.75 by +6.02%, while revenue for the quarter reached $1.54m , missing expectations by -5.68%.
Earnings released on 5 Aug 2021
EPS came in at -$19.75 surpassing the estimated -$20.25 by +2.47%, while revenue for the quarter reached $1.55m , meeting expectations.
ALGS Stock Performance
Access detailed ALGS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
